陽光諾和(688621.SH):向上交所申請中止審核本次重組事項
格隆匯6月29日丨陽光諾和(688621.SH)公佈,公司擬通過發行股份及支付現金方式購買北京朗研生命科技控股有限公司(簡稱“朗研生命”)100%股權,並向不超過35名特定投資者發行股份募集配套資金(簡稱“本次交易”)。
截至目前,相關財務資料有效期接近到期,為保證審核期間財務數據的有效性,需對相關財務數據進行加期審計,並補充提交相關文件,公司特向上交所申請中止審核本次重組事項,並將在財務數據更新完畢後申請恢復審核。本次中止審核事項不會對公司生產經營產生重大不利影響,公司與相關中介機構正在積極推進本次重組的加期審計等相關工作,待相關工作完成後,公司將立即向上交所申請恢復審核。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.